Gelofusine (R) affects the quality control performance of QuickVue (R) point-of-care human chorionic gonadotropin test devices

D. de Boer*, C. Houben, O. Bekers, P.P.C.A. Menheere

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


OBJECTIVE: To characterize the influence of Gelofusine (succinylated gelatin) on the performance of point-of-care testing (POCT) for human chorionic gonadotropin (hCG) devices. DESIGN AND METHODS: Three brands of urine and urine/serum hCG POCT devices were verified. RESULTS: Succinylated gelatin affected the performance of the control band in the QuickVue hCG POCT devices. Alternative devices were not affected. The hCG test performance is not influenced. CONCLUSIONS: Gelofusine affects specifically the quality control performance of the QuickVue hCG POCT devices.
Original languageEnglish
Pages (from-to)1371-1372
Number of pages2
JournalClinical Biochemistry
Issue number16-17
Publication statusPublished - Nov 2010


  • Pregnancy test
  • Point-of-care
  • hCG urine
  • Gelofusine
  • Quality control
  • HCG

Cite this